Correlation Between Neurobo Pharmaceuticals and Achilles Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Neurobo Pharmaceuticals and Achilles Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurobo Pharmaceuticals and Achilles Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Neurobo Pharmaceuticals and Achilles Therapeutics PLC, you can compare the effects of market volatilities on Neurobo Pharmaceuticals and Achilles Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurobo Pharmaceuticals with a short position of Achilles Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurobo Pharmaceuticals and Achilles Therapeutics.

Diversification Opportunities for Neurobo Pharmaceuticals and Achilles Therapeutics

-0.86
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Neurobo and Achilles is -0.86. Overlapping area represents the amount of risk that can be diversified away by holding Neurobo Pharmaceuticals and Achilles Therapeutics PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Achilles Therapeutics PLC and Neurobo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurobo Pharmaceuticals are associated (or correlated) with Achilles Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Achilles Therapeutics PLC has no effect on the direction of Neurobo Pharmaceuticals i.e., Neurobo Pharmaceuticals and Achilles Therapeutics go up and down completely randomly.

Pair Corralation between Neurobo Pharmaceuticals and Achilles Therapeutics

Given the investment horizon of 90 days Neurobo Pharmaceuticals is expected to under-perform the Achilles Therapeutics. In addition to that, Neurobo Pharmaceuticals is 2.58 times more volatile than Achilles Therapeutics PLC. It trades about -0.16 of its total potential returns per unit of risk. Achilles Therapeutics PLC is currently generating about 0.23 per unit of volatility. If you would invest  99.00  in Achilles Therapeutics PLC on August 28, 2024 and sell it today you would earn a total of  8.00  from holding Achilles Therapeutics PLC or generate 8.08% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Neurobo Pharmaceuticals  vs.  Achilles Therapeutics PLC

 Performance 
       Timeline  
Neurobo Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Neurobo Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.
Achilles Therapeutics PLC 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.

Neurobo Pharmaceuticals and Achilles Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Neurobo Pharmaceuticals and Achilles Therapeutics

The main advantage of trading using opposite Neurobo Pharmaceuticals and Achilles Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurobo Pharmaceuticals position performs unexpectedly, Achilles Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achilles Therapeutics will offset losses from the drop in Achilles Therapeutics' long position.
The idea behind Neurobo Pharmaceuticals and Achilles Therapeutics PLC pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets